EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Glucosylceramide Synthase: Innovative Drug Repurposing Strategies for Lysosomal Diseases

Giorgia Canini, Elena Mazzinelli iD, Giuseppina Nocca iD, Wanda Lattanzi iD, Alessandro Arcovito iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26052195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Giorgia Canini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo Francesco Vi…. Hauptthemen laut MEDLINE: Glucosyltransferases, Drug Repositioning, Enzyme Inhibitors, Lysosomal Storage Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore, Linea D1 Università Cattolica del Sacro Cuore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sphingolipidoses, a subgroup of lysosomal storage diseases (LSDs), are rare and debilitating disorders caused by defects in sphingolipid metabolism. Despite advancements in treatment, therapeutic options remain limited. Miglustat, a glucosylceramide synthase EC 2.4.1.80 (GCS) inhibitor, is one of the few available pharmacological treatments; however, it is associated with significant adverse effects that impact patients’ quality of life. Drug repurposing offers a promising strategy to identify new therapeutic agents from approved drugs, expanding treatment options for rare diseases with limited therapeutic alternatives. This study aims to identify potential alternative inhibitors of GCS through a drug-repurposing approach, using computational and experimental methods to assess their therapeutic potential for sphingolipidoses. A library of approved drugs was screened using advanced computational techniques, including molecular docking, molecular dynamics simulations, and metadynamics, to identify potential GCS inhibitors. Promising candidates were selected for further in vitro validation to evaluate their inhibitory activity and potential as therapeutic alternatives to Miglustat. Computational screening identified several potential GCS inhibitors, with Dapagliflozin emerging as the most promising candidate. Experimental validation confirmed its efficacy, revealing a complementary mechanism of action to Miglustat while potentially offering a more favorable side effect profile. This study underscores the utility of computational and experimental methodologies in drug repurposing for rare diseases. The identification of Dapagliflozin as a potential GCS inhibitor provides a foundation for further preclinical and clinical evaluation, supporting its potential application in the treatment of sphingolipidoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosyltransferasesDrug RepositioningEnzyme InhibitorsLysosomal Storage DiseasesHumansMolecular Docking SimulationMolecular Dynamics Simulation1-Deoxynojirimycin

Stichwörter der Autor:innen

cross-dockingdrug repurposinglysosomal storage diseasesmolecular dynamics simulationssphingolipidosesvirtual screening

Substanzen

Glucosyltransferasesceramide glucosyltransferaseEnzyme Inhibitorsmiglustat1-Deoxynojirimycin

Autor:innen und Institutionen

  • Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.
  • Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy.
  • Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.

ORCID-Profile: Elena Mazzinelli, Giuseppina Nocca, Wanda Lattanzi, Alessandro Arcovito

Förderung

  • Università Cattolica del Sacro Cuore
  • Linea D1 Università Cattolica del Sacro Cuore

Zitieren

APA

Canini, G., Mazzinelli, E., Nocca, G., Lattanzi, W., & Arcovito, A. (2025). Targeting Glucosylceramide Synthase: Innovative Drug Repurposing Strategies for Lysosomal Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052195

Vancouver

Canini G, Mazzinelli E, Nocca G, Lattanzi W, Arcovito A. Targeting Glucosylceramide Synthase: Innovative Drug Repurposing Strategies for Lysosomal Diseases. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052195

BibTeX
@article{Canini2025,
  author = {Canini, Giorgia and Mazzinelli, Elena and Nocca, Giuseppina and Lattanzi, Wanda and Arcovito, Alessandro},
  title = {Targeting Glucosylceramide Synthase: Innovative Drug Repurposing Strategies for Lysosomal Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26052195}
}
Kostenlos starten →